Lv11
58 积分 2024-06-14 加入
P89: Stability of Psoriasis Area and Severity Index < 2 response to tildrakizumab through 5 years: pooled analyses from reSURFACE 1 and reSURFACE 2 phase III trials
2小时前
已关闭
A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response
2个月前
已完结
Specific targeting of interleukin-23p19 as effective treatment for psoriasis
2个月前
已完结
Novel anti-psoriasis agent-associated cardiotoxicity, analysis of the FDA adverse event reporting system (FAERS)
2个月前
已完结
皖公网安备34019202002308
